Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale
For Q2 2023 and the first half of the Q3 2023, we have been heavily focused on ongoing conversations around promising innovations.
- For Q2 2023 and the first half of the Q3 2023, we have been heavily focused on ongoing conversations around promising innovations.
- We also mutually agreed to terminate the non-binding letter of intent with Natural State Genomics and Natural State Laboratories.
- Since the founding of Aditxt, we have believed that commercializing health innovations deserves a new approach driven by stakeholders.
- Continuing to expand product pipeline, research, and development, and have wider commercial reach with patients with a POC testing platform.